[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of South Alabama\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":100},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100640051","effects-of-timed-restricted-eating-on-body-composition-metabolism-and-cardiovascular-health-100640051",false,"NCT07574177","Effects of Timed Restricted Eating on Body Composition, Metabolism, and Cardiovascular Health","The Effect of Timed Restricted Eating With or Without Intermittent Energy Restriction on Measures of Body Composition, Resting Energy Expenditure, Cardiovascular Modulation, and Blood Biomarkers Over 12 Weeks","Inclusion Criteria:\n\n* Between 18 and 65 years of age\n* Body mass index (BMI) of 26 kg\u002Fm² or higher (overweight or obese range)\n* Physically inactive, defined as 150 minutes or less of moderate-intensity physical activity per week for the 3 months prior to enrollment\n* No previous history of cardiovascular disease or Type 1 or Type 2 Diabetes Mellitus\n* Not currently taking medications that may affect blood sugar, cholesterol, or body weight (e.g., glucose-lowering drugs, statins, or weight loss medications)\n* Weight stable, defined as no more than 5 kg (about 11 lbs.) of body weight change in the 3 months prior to enrollment\n* Willing and able to follow the study requirements, provide voluntary consent, and complete all study procedures\n\nExclusion Criteria:\n\n* Younger than 18 or older than 65 years of age\n* BMI below 26 kg\u002Fm²\n* More than 150 minutes per week of moderate-intensity physical activity in the past 3 months\n* History of cardiovascular disease or Type 1 or Type 2 Diabetes Mellitus\n* Currently taking medications that may impact study outcomes\n* Weight change of more than 5 kg in the past 3 months\n* Pregnant, breastfeeding, or planning to become pregnant during the study\n* History of an eating disorder\n* Previous weight loss surgery (e.g., gastric bypass or sleeve gastrectomy)\n* Unable to fast for approximately 18 hours at a time due to a medical condition\n* Currently working night shifts\n* Has a pacemaker or any implanted electronic device (due to bioimpedance spectroscopy testing)\n* Any health condition the research team determines would put the participant at risk",true,"ALL","18 Years","65 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is looking at whether eating all meals within a 6-hour window each day (called Time-Restricted Eating, or TRE) can improve body composition, metabolism, heart health, and blood markers over 12 weeks. The study also wants to find out whether allowing participants to eat normally on weekends makes the diet easier to follow long-term.\n\nAdults aged 18-65 with a BMI of 26 or higher who do not have heart disease or diabetes may be eligible. Participants will be randomly placed into one of two groups: (1) TRE every day for 12 weeks, or (2) TRE on weekdays with normal eating on weekends. All participants will visit the lab twice - once at the start and once at the end - for measurements of body fat, resting calorie burn, heart function, and blood tests. Between visits, participants will log their meals and steps at home and check in with the research team every two weeks.",[28],"Intermittent Fasting",[30,31,32,33,34],"Time-Restricted Eating","body composition","obesity","weight management","intermittent fasting","NOT_YET_RECRUITING","2026-05-07",{"date":38,"type":39},"2026-05-12","ACTUAL",{"date":41,"type":22},"2026-07",{"date":43,"type":22},"2027-07",{"name":45,"class":46},"University of South Alabama","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":19,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100552023","low-voltage-electrical-stimulation-for-depression-in-parkinsons-patients-100552023","NCT06467695","Low Voltage Electrical Stimulation for Depression in Parkinson's Patients","The Effect of MRI-Guided Transcranial Direct Current Stimulation on Cognitive and Affective Symptoms in Persons With Parkinson's Disease and Controls","LVESDIPP","Inclusion Criteria:\n\n* 19 to 65 years in age.\n* Parkinson's Group must have a physician dx of Parkinson's Disease\n* Must meet exhibit elevated levels of depression on the Beck Depression Inventory (scores of 20 or above).\n* Must be willing and able to travel of the Psychology Department for EEG and tDCS sessions.\n* Participants who have undergone surgery for Deep Brain Stimulation implantation may be enrolled if advised to and monitored by their physician.\n* Read and understand spoken English.\n\nExclusion Criteria:\n\n* No history of or being treated for epilepsy or other seizure disorders.\n* No history of penetrating head wounds or TBI greater than mild TBI.\n* No history of atypical Parkinson's","19 Years",{"count":57,"type":22},40,[25],"The goal of this clinical trial is to determine the relative efficacy of fMRI model guided Transcranial Direct Current Stimulation (mgTDCS) in improving the depressive symptoms of patients with Parkinson's Disease (PD). The main questions it aims to answer are: 1) Can the use of mgTDCS significantly improve the self-reported level of depression and apathy in patients with PD from pre-intervention to post-intervention compared to a sham control? 2) Can the use of mgTDCS significantly normalize the cortical eeg alpha asymmetry so commonly seen in depressed patients compared to sham mgTDCS? 3) Can the use of mgTDCS significantly improve scores on neuropsychological tests of working memory?",[61,62],"Parkinson Disease","Depressive Symptoms",[64],"Direct Transcranial Current Stimulation","RECRUITING","2026-04-01",{"date":68,"type":39},"2026-04-06",{"date":70,"type":39},"2024-08-01",{"date":72,"type":22},"2027-06-30",{"name":45,"class":46},1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":74},"100614231","phase-4-comparing-intramuscular-fentanyl-and-ketorolac-with-nerve-of-arnold-noa-block-for-bilateral-myringotomy-100614231","NCT07276906","Comparing Intramuscular Fentanyl and Ketorolac With Nerve of Arnold (NOA) Block for Bilateral Myringotomy","A Prospective, Randomized, Double-Blind, Non-Inferiority Trial Comparing Intramuscular Fentanyl and Ketorolac With Nerve of Arnold Block for Postoperative Pain Management in Pediatric Patients Undergoing Bilateral Myringotomy With Tympanostomy Tube Placement","NOA","Inclusion Criteria:\n\nAge 6 months to 6 years\n\nScheduled bilateral myringotomy with tube placement\n\nASA physical status I-II\n\nParent\u002Fguardian consent\n\nExclusion Criteria:\n\n* Allergy to study medications (fentanyl, ketorolac, bupivacaine)\n\nRenal impairment or contraindication to ketorolac\n\nBleeding disorder or anticoagulation\n\nSignificant obstructive sleep apnea (AHI \\>10)\n\nConcurrent surgical procedures beyond BMT\n\nUnilateral procedure only\n\nRecent analgesic use (\\\u003C24 hours)","6 Months","6 Years",{"count":86,"type":22},300,[88],"PHASE4","Background: Bilateral myringotomy with tympanostomy tube (BMT) placement is one of the most common pediatric surgical procedures. Despite its brief duration, many children experience significant postoperative pain. Current standard care typically involves intramuscular (IM) administration of an opioid (fentanyl) combined with a non-steroidal anti-inflammatory drug (ketorolac). While this multimodal approach provides adequate pain control for approximately 75% of children, it is associated with opioid-related side effects including respiratory depression, nausea, vomiting, and sedation. Additionally, nearly one-quarter of children still experience moderate-to-severe pain despite this regimen.\n\nThe Nerve of Arnold block is a regional anesthesia technique that involves injection of local anesthetic near the auricular branch of the vagus nerve, which provides sensory innervation to the external auditory canal and tympanic membrane. This technique offers the potential for targeted, opioid-sparing analgesia with extended duration and minimal systemic side effects. However, high-quality evidence comparing this regional technique to standard systemic analgesia in pediatric patients is lacking.\n\nStudy Objective: This study aims to determine whether the Nerve of Arnold block is non-inferior to the standard combination of IM fentanyl and IM ketorolac in controlling postoperative pain in children undergoing BMT placement.\n\nStudy Design: This is a prospective, randomized, double-blind, non-inferiority trial. Three hundred children aged 6 months to 6 years scheduled for bilateral myringotomy with tympanostomy tube placement will be randomized 1:1 to receive either: (1) Standard care: IM fentanyl (1-2 mcg\u002Fkg) plus IM ketorolac (0.5 mg\u002Fkg) with sham Nerve of Arnold block, or (2) Intervention: Bilateral Nerve of Arnold block with bupivacaine 0.25% plus sham IM injections. Both patients and outcome assessors will be blinded to treatment assignments.\n\nPrimary Outcome: The proportion of patients experiencing moderate-to-severe pain (Face, Legs, Activity, Cry, Consolability \\[FLACC\\] scale score ≥4) in the Post-Anesthesia Care Unit (PACU). Non-inferiority will be declared if the upper bound of the 95% confidence interval for the difference in proportions is less than 10 percentage points.\n\nSecondary Outcomes: Secondary outcomes include mean and maximum FLACC scores, rescue analgesic requirements, respiratory depression, postoperative nausea and vomiting, PACU length of stay, parent satisfaction, and pain at 24 hours postoperatively.\n\nClinical Significance: If the Nerve of Arnold block is shown to be non-inferior to standard care, it could provide a valuable opioid-sparing alternative for postoperative pain management in pediatric ear surgery, potentially reducing opioid-related adverse events while maintaining effective analgesia. This would be particularly beneficial for patients with contraindications to opioids or NSAIDs and aligns with national efforts to reduce opioid exposure in pediatric populations.",[91],"Postoperative Pain","2025-12-01",{"date":94,"type":39},"2025-12-11",{"date":96,"type":22},"2026-01",{"date":98,"type":22},"2026-08",{"name":45,"class":46},""]